ZEISS India signs a multi-year strategic partnership with Dr. Agarwal’s Eye Hospital and Narayana Nethralaya
NiveshIQ
Dr. Agarwal's Health Care Ltd.
NiveshIQ has detected 5 active signals on AGARWALEYE. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeAbout Dr. Agarwal's Health Care Ltd.
Dr. Agarwal's Health Care Limited (AGARWALEYE) operates a diversified eye‑care portfolio that includes hospitals, opticals, pharmacies and a range of surgical services such as femto‑cataract, retinal and corneal procedures. The company also designs, manufactures and exports ophthalmic diagnostic devices, generating a significant portion of its revenue from auto‑perimeters, optical biometers and ophthalmoscopes. In FY26 the firm reported ₹2,207 Cr in revenue and ₹148 Cr in net income, reflecting a 12% YoY revenue growth and a 9% increase in net profit. Recent developments include the closure of its Q2 FY27 trading window and the approval of director pay revisions at the 16th AGM, indicating stable governance. Competitively, Dr. Agarwal’s holds a strong market position in India’s premium eye
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹1,328 Cr +30.40% | ₹1,711 Cr +28.90% | ₹2,080 Cr +21.57% |
| EBITDA Margin | 28.89% | 26.67% | 27.38% |
| Net Profit | ₹83.06 Cr -19.40% | ₹83.46 Cr +32.40% | ₹133.19 Cr +59.59% |
| EPS | – | ₹2.80 | ₹4.21 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
ZEISS India Signs Strategic Pact With Dr. Agarwal’s and Narayana Nethralaya for Advanced Eye Care
ZEISS India Signs A Multi-Year Strategic Partnership With Dr. Agarwal’s Eye Hospital And Narayana Nethralaya.
Strategic Outlook
- Q1FY27 results: revenue ₹614 Cr, PAT ₹55 Cr, EPS ₹1.43, EBITDA margin 28.8%. Growth context: revenue QoQ +8.8%, PAT QoQ +13.1%. Street verdict: strong beat, revenue surprise +3.7%, PAT surprise +57.8%.
Recent corporate activity highlights product launches, approvals, and therapy-mix improvement and new product launches a...
FY26 (last completed FY): revenue ₹2, 080 Cr, PAT ₹167 Cr, EBITDA margin 29.5%, EPS ₹4.21. Year-on-year: revenue YoY +21...
More Healthcare stocks
Everything you unlock with a free account
Frequently Asked Questions
What AI signals does NiveshIQ provide for Dr. Agarwal's Health Care Ltd.?
NiveshIQ detects active intelligence signals for Dr. Agarwal's Health Care Ltd. (AGARWALEYE) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Dr. Agarwal's Health Care Ltd.?
Dr. Agarwal's Health Care Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,437,403.5L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.